The Angeles Clinic & Research Institute | May 6, 2023
…Therapy in Melanoma, Novel Paradigms Stephen L. Shiao, MD, PhD Department of Radiation Oncology Cedars-Sinai Medical Center Seeking Answers: Ocular…
The Angeles Clinic & Research Institute | May 6, 2023
…Therapy in Melanoma, Novel Paradigms Stephen L. Shiao, MD, PhD Department of Radiation Oncology Cedars-Sinai Medical Center Seeking Answers: Ocular…
UW Carbone Cancer Center| May 20, 2023
…and insights from patients with melanoma https://youtu.be/xCTBbAU75ag 11:25 AM CT Closing Remarks Ann Garst Taylor Director of Community Engagement AIM…
The Benefits of Clinical Trials
…used in clinical trials for people with melanoma because there are several approved treatments. Read more about placebos in melanoma…
Atrium Health Levine Cancer | Nov. 11, 2023
…and caregivers to learn about melanoma from medical professionals and fellow patients, caregivers, and survivors. This event is FREE and open to…
Sarah Cannon Research Institute | Saturday, Nov. 2, 2024
…MD, MPH Medical Oncologist Director, Melanoma and Skin Cancer Research Sarah Cannon Research Personalizing Your Melanoma Treatment Thomas Amatruda,…
TIL Therapy
…Therapy and What it Means for Advanced Melanoma Written and Edited Transcript of Webinar on TIL Therapy In Plain English:…
Advisory Board
…twice served as president of school parents’ associations. Ms. Kingham is excited to support AIM at Melanoma in its mission…
Sarah Cannon Research Institute | Saturday, Nov. 2, 2024
…Time: 11:00 AM ET| 10:00 AM CT| 9:00 AM MT| 8:00 AM PT Format: Presented virtually Presenters & Topics Preventing Melanoma Meredith…
Oregon vs. Melanoma — Uniting to Defeat Deadly Skin Cancer | May 10, 2022
…EngageUs@AIMatMelanoma.org Presenters & Topics Opening & Welcome Sancy Leachman, M.D., Ph.D., Chair of the Department of Dermatology at OHSU and the Melanoma…
After Treatment
Living as a Melanoma Survivor Completing melanoma treatment can be both relieving and stressful. You may be relieved because you’ve…
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026